A detailed history of Bay Colony Advisory Group, Inc D transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Bay Colony Advisory Group, Inc D holds 10,747 shares of CTMX stock, worth $36,862. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,747
Holding current value
$36,862
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 23, 2025

BUY
$1.76 - $3.23 $18,914 - $34,712
10,747 New
10,747 $34,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $226M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Bay Colony Advisory Group, Inc D Portfolio

Follow Bay Colony Advisory Group, Inc D and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bay Colony Advisory Group, Inc D, based on Form 13F filings with the SEC.

News

Stay updated on Bay Colony Advisory Group, Inc D with notifications on news.